Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QLS2406-1
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Administration
- Parenteral
01
Overview
QLS2406-1 is an investigational Class 1 innovative biologic being developed by Qilu Pharmaceutical for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). It is designed as a multi-target combination therapeutic that simultaneously acts on multiple key metabolic regulatory pathways to improve hepatic steatosis, reduce liver inflammation, and alleviate liver fibrosis. In October 2026, QLS2406-1 received clinical trial approval (IND) from the Chinese Center for Drug Evaluation (CDE).
Beyond the preview
Go deeper on QLS2406-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QLS2406-1.